Literature DB >> 19699208

The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators.

Nazzareno Dimasi1, Changshou Gao, Ryan Fleming, Robert M Woods, Xiao-Tao Yao, Lena Shirinian, Peter A Kiener, Herren Wu.   

Abstract

Monoclonal antibodies are traditionally used to block the function of a specific target in a given disease. However, some diseases are the consequence of multiple components or pathways and not the result of a single mediator; thus, blocking at a single point may not optimally control disease. Antibodies that simultaneously block the functions of two or more disease-associated targets are now being developed. Herein, we describe the design, expression, and characterization of several oligospecific antibody formats that are capable of binding simultaneously to two or three different antigens. These constructs were generated by genetically linking single-chain Fv fragments to the N-terminus of the antibody heavy and light chains and to the C-terminus of the antibody C(H)3 domain. The oligospecific antibodies were expressed in mammalian cells, purified to homogeneity, and characterized for binding to antigens, Fcgamma receptors, FcRn, and C1q. In addition, the oligospecific antibodies were assayed for effector function, protease susceptibility, thermal stability, and size distribution. We demonstrate that these oligospecific antibody formats maintain high expression level, thermostability, and protease resistance. The in vivo half-life, antibody-dependent cellular cytotoxicity function, and binding ability to Fcgamma receptors and C1q of the test oligospecific antibodies remain similar to the corresponding properties of their parental IgG antibodies. The excellent expression, biophysical stability, and potential manufacturing feasibility of these multispecific antibody formats suggest that they will provide a scaffold template for the construction of similar molecules to target multiple antigens in complex diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19699208     DOI: 10.1016/j.jmb.2009.08.032

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  36 in total

1.  Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity.

Authors:  Jianying Dong; Arlene Sereno; William B Snyder; Brian R Miller; Susan Tamraz; Adam Doern; Michael Favis; Xiufeng Wu; Hon Tran; Emma Langley; Ingrid Joseph; Antonio Boccia; Rebecca Kelly; Kathleen Wortham; Qin Wang; Lisa Berquist; Flora Huang; Sharon X Gao; Ying Zhang; Alexey Lugovskoy; Shelly Martin; Heather Gouvis; Steven Berkowitz; Gisela Chiang; Mitchell Reff; Scott M Glaser; Kandasamy Hariharan; Stephen J Demarest
Journal:  J Biol Chem       Date:  2010-12-01       Impact factor: 5.157

Review 2.  Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis.

Authors:  Jamie Campbell; David Lowe; Matthew A Sleeman
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

3.  Biodistribution Analyses of a Near-Infrared, Fluorescently Labeled, Bispecific Monoclonal Antibody Using Optical Imaging.

Authors:  Norman C Peterson; George G Wilson; Qihui Huang; Nazzareno Dimasi; Kris F Sachsenmeier
Journal:  Comp Med       Date:  2016-04       Impact factor: 0.982

4.  High-throughput measurement, correlation analysis, and machine-learning predictions for pH and thermal stabilities of Pfizer-generated antibodies.

Authors:  Amy C King; Matthew Woods; Wei Liu; Zhijian Lu; Davinder Gill; Mark R H Krebs
Journal:  Protein Sci       Date:  2011-07-13       Impact factor: 6.725

5.  Fab-based bispecific antibody formats with robust biophysical properties and biological activity.

Authors:  Xiufeng Wu; Arlene J Sereno; Flora Huang; Steven M Lewis; Ricky L Lieu; Caroline Weldon; Carina Torres; Cody Fine; Micheal A Batt; Jonathan R Fitchett; Andrew L Glasebrook; Brian Kuhlman; Stephen J Demarest
Journal:  MAbs       Date:  2015       Impact factor: 5.857

6.  Guiding bispecific monovalent antibody formation through proteolysis of IgG1 single-chain.

Authors:  Nazzareno Dimasi; Ryan Fleming; Kris F Sachsenmeier; Binyam Bezabeh; Carl Hay; Jincheng Wu; Erin Sult; Saravanan Rajan; Li Zhuang; Peter Cariuk; Andrew Buchanan; Michael A Bowen; Herren Wu; Changshou Gao
Journal:  MAbs       Date:  2017-01-05       Impact factor: 5.857

7.  Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties.

Authors:  Binyam Bezabeh; Ryan Fleming; Christine Fazenbaker; Haihong Zhong; Karen Coffman; Xiang-Qing Yu; Ching Ching Leow; Nerea Gibson; Susan Wilson; C Kendall Stover; Herren Wu; Changshou Gao; Nazzareno Dimasi
Journal:  MAbs       Date:  2017 Feb/Mar       Impact factor: 5.857

8.  Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

Authors:  Aran F Labrijn; Joyce I Meesters; Bart E C G de Goeij; Ewald T J van den Bremer; Joost Neijssen; Muriel D van Kampen; Kristin Strumane; Sandra Verploegen; Amitava Kundu; Michael J Gramer; Patrick H C van Berkel; Jan G J van de Winkel; Janine Schuurman; Paul W H I Parren
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-11       Impact factor: 11.205

9.  Crystal structure of the human 4-1BB/4-1BBL complex.

Authors:  Ryan N Gilbreth; Vaheh Y Oganesyan; Hamza Amdouni; Shabazz Novarra; Luba Grinberg; Arnita Barnes; Manuel Baca
Journal:  J Biol Chem       Date:  2018-05-02       Impact factor: 5.157

10.  Fibronectin type III domains engineered to bind CD40L: cloning, expression, purification, crystallization and preliminary X-ray diffraction analysis of two complexes.

Authors:  Vaheh Oganesyan; Andrew Ferguson; Luba Grinberg; Lin Wang; Sandrina Phipps; Benoy Chacko; Stacey Drabic; Thomas Thisted; Manuel Baca
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.